Thought leaders in breast oncology share closing remarks about the future management of HER2+ BC with brain metastases with key insights on unmet needs and evolving treatment approaches.
In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Authors Dori Beeler, PhD; Shelley Wang, MD, MPH; and Viraj A. Master, MD, PhD, spoke with CancerNetwork® about a review article on cancer-related fatigue published in the journal ONCOLOGY®.
This review article written by Robert Stuver, MD, et al, reviews current and available treatments for peripheral T-cell lymphoma.
A multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.
A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.
A phase 2 study has begun recruiting patients with relapsed/refractory acute myeloid leukemia to test the efficacy of magrolimab.
Phillip S. Low, PhD, spoke about what the future holds for treatments like 177Lu-PSMA-617 being developed for patients with prostate cancer.
A multitude of factors contributes to cancer disparities. Addressing these disparities among racial/ethnic minority populations with blood cancers requires multilevel models of the interactions between relevant factors and the performance of translational research that uses knowledge of cancer biology to develop and test the feasibility of interventions that can impact human endpoints. To be effective, efforts should be made to advance these research findings to applications that can transform clinical practice and health care delivery. We reviewed the literature to define a framework for overcoming disparities for patients with hematologic malignancies and to improve patient enrollment in clinical trials.
Aaron Berger, MD, discussed updates in the treatment of nonmetastatic castration-resistant prostate cancer.
A nulliparous woman, age 25 years, had received a diagnosis of non-Hodgkin lymphoma and now presented with stage IIA diffuse large B-cell lymphoma. Due to potential risks of chemotherapy-induced gonadotoxicity and subsequent iatrogenic premature ovarian failure and fertility loss, the patient was referred to the reproductive medicine department for fertility preservation counseling and further management.
Looking forward, Andrzej Jakubowiak, MD, PhD, anticipates CAR T-cell therapy with ciltacabtagene autoleucel will establish its place across various indications for multiple myeloma.
The panel shares some final thoughts on unmet needs and the future of CLL treatment.
Nora Biran, MD, and David Siegel, MD, offer closing remarks on the MM treatment landscape.
In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.
Alberto Calvo-García, PharmG, and colleagues analyzed routinely-collected data to assess regorafenib in metastatic colorectal cancer.
Patients 70 years or older that received neoadjuvant chemotherapy and radical cystectomy had better overall survival than those undergoing radical cystectomy alone.
A 57-year-old man with a heavy smoking and alcohol consumption history, but no comorbidities, presented with pharyngeal pain to his primary care physician’s office. He received empirical treatment with oral antibiotics and experienced partial improvement. A couple of months later, he developed a left cervical mass with progressive growth. A head and neck CT scan revealed a hypopharyngeal tumor. Results of a tumor biopsy indicated an ulcerated, moderately differentiated squamous cell carcinoma (SCC) with lymphovascular invasion. The patient was sent to our institution for treatment.
Investigators support individualized approaches and compassionate care to minimize nonmedical opioid use and opioid use disorder in patients with cancer pain.
Kohie Shitara, MD, spoke about the use of immunotherapy in the first-line setting for metastatic gastric cancer.